Affinage

ARID3A

AT-rich interactive domain-containing protein 3A · UniProt Q99856

Length
593 aa
Mass
62.9 kDa
Annotated
2026-06-09
100 papers in source corpus 26 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARID3A (Bright/DRIL1/E2FBP1) is a nuclear ARID-domain transcription factor that binds AT-rich promoter and enhancer sequences to direct context-specific gene activation or repression governing lymphocyte development, stem-cell/lineage fate, and epigenetic chromatin state (PMID:11594453, PMID:24511468, PMID:25319825). It was first defined as an activator of immunoglobulin heavy chain (IgH) transcription, acting within a Bright–Btk–TFII-I complex at the IgH locus and countering nucleosome-mediated repression at the Eμ enhancer in a manner requiring matrix attachment region sequences to increase chromatin accessibility (PMID:16738337, PMID:17386101). ARID3A operates as a barrier to developmental plasticity: it directly binds and represses the pluripotency genes Oct4, Sox2, and Nanog while activating lineage-specific programs, driving trophectoderm commitment and placentation through nuclear translocation triggered by developmental cues such as BMP4 (PMID:24511468, PMID:25319825, PMID:27965054). In hematopoiesis it is a downstream effector of Lin28b/let-7 sufficient to instruct B-1 lymphopoiesis, cooperates with GATA1 and SMAD2/3 to promote megakaryocytic differentiation and TGF-β-induced apoptosis, and is repressed by miR-125b in acute megakaryoblastic leukemia (PMID:25753579, PMID:34570885). ARID3A also functions through epigenetic complexes—reducing H3K9me3 at regeneration enhancers and partnering with CEP131 to activate the demethylase KDM3A—and exerts context-dependent control over cell cycle and tumor phenotypes by cooperating with p53 to activate p21WAF1 and by transcriptionally regulating AURKA, PTEN, and Mertk (PMID:30616715, PMID:36008383, PMID:22172947, PMID:33165575, PMID:38781729, PMID:37659731). Its DNA binding is modulated by partners including Btk-dependent TFII-I phosphorylation and inhibitory Id1 interaction, integrating ARID3A into TGF-β/Smad signaling (PMID:16738337, PMID:18583319, PMID:15680369).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 1998 Medium

    Established the molecular identity of ARID3A as a chromosome 19p13.3 gene encoding an ARID-family DNA-binding protein, providing the structural foundation for all functional work.

    Evidence cDNA cloning and genomic/physical mapping

    PMID:9722953

    Open questions at the time
    • No functional or binding-site data
    • ARID-domain DNA specificity not defined here
  2. 2001 Medium

    Showed that ARID3A binds AT-rich DNA via its ARID domain to activate IgH transcription, and that Btk is required for its DNA-binding activity, linking it to B-cell receptor signaling.

    Evidence DNA binding and reporter assays, protein-interaction studies in B cells

    PMID:11594453

    Open questions at the time
    • Mechanism of Btk dependence not resolved
    • sp100/LYSp100B functional role unclear
  3. 2005 High

    Placed ARID3A genetically within TGF-β signaling, showing it is specifically required for activin/Smad2 and BMP/Smad1 (but not FGF) responses during embryonic germ-layer induction.

    Evidence Morpholino knockdown with mRNA rescue and pathway epistasis in Xenopus

    PMID:15680369

    Open questions at the time
    • Direct Smad-ARID3A interaction not shown
    • Target genes in embryo not mapped
  4. 2006 High

    Resolved the IgH activation complex by mapping a three-component Bright–Btk–TFII-I assembly, with Btk-dependent TFII-I tyrosine phosphorylation required for ARID3A-driven transcription.

    Evidence Reciprocal Co-IP, interaction mapping with mutants, dominant-negative and reporter assays in B-cell lines

    PMID:16738337

    Open questions at the time
    • Stoichiometry/architecture of the complex undefined
    • Generality beyond IgH locus untested
  5. 2007 High

    Defined the chromatin mechanism of ARID3A at the IgH Eμ enhancer, showing it relieves nucleosome-mediated repression and increases DNase hypersensitivity in a MAR-dependent manner.

    Evidence In vitro transcription on reconstituted chromatin and DNase I hypersensitivity assays

    PMID:17386101

    Open questions at the time
    • No chromatin-remodeler partner identified
    • In vivo enhancer state not assayed
  6. 2003 Medium

    Connected ARID3A to the p53/DNA-damage axis, showing it is a p53 transcriptional target that induces p53-dependent G1 arrest.

    Evidence p53-binding-site reporter, DNA-damage induction, growth arrest in isogenic p53+/null cells

    PMID:12692263

    Open questions at the time
    • Direct ARID3A target genes mediating arrest not identified here
    • Single-lab
  7. 2011 High

    Established a reciprocal ARID3A–p53 circuit by showing ARID3A directly binds the p21WAF1 promoter and cooperates with p53 to selectively activate p21 while modulating p53 protein stability.

    Evidence ChIP, EMSA, mutant reporters, siRNA knockdown, western blot

    PMID:22172947

    Open questions at the time
    • Mechanism of p53 stabilization unresolved
    • Selectivity for p21 over NOXA/PUMA unexplained
  8. 2008 Medium

    Identified Id1 as a negative regulator that binds ARID3A and blocks its DNA binding, suppressing ARID3A's profibrotic TGF-β1 target activation.

    Evidence Yeast two-hybrid, co-localization, DNA-binding competition, target gene analysis in Id1-KO fibroblasts

    PMID:18583319

    Open questions at the time
    • Direct profibrotic targets not enumerated
    • Single-lab interaction screen
  9. 2010 Medium

    Revealed ARID3A as a restraint on developmental plasticity, since its loss yields cells expressing pluripotency markers and capable of multi-lineage differentiation.

    Evidence Two mouse loss-of-function models, colony/lineage assays, human ARID3A knockdown

    PMID:20680960

    Open questions at the time
    • Direct target genes not mapped in this study
    • Mechanism of plasticity not yet molecular
  10. 2014 High

    Provided the molecular basis for plasticity restraint, demonstrating ARID3A directly binds and represses Oct4/Sox2/Nanog promoters to act as a barrier to somatic reprogramming.

    Evidence ChIP at pluripotency promoters, MEF reprogramming, teratoma/chimera assays in knockout cells

    PMID:24511468

    Open questions at the time
    • Repressive co-factor/complex not identified
    • Mechanism of senescence bypass unresolved
  11. 2014 High

    Showed ARID3A drives trophectoderm fate via nuclear entry that activates TE genes and epigenetically represses pluripotency genes, acting upstream of and independently of Cdx2.

    Evidence ChIP for histone marks, Arid3a-/- mice, ES/trophoblast stem cell gain-of-function, epistasis

    PMID:25319825

    Open questions at the time
    • Enzymes mediating acetylation/deacetylation at targets not identified
    • Translocation trigger not defined here
  12. 2016 Medium

    Established ARID3A's requirement for placentation and identified BMP4 as a cue triggering its cytoplasmic-to-nuclear translocation to reprogram TE vs pluripotency markers.

    Evidence IHC/IF localization, conventional KO mice, overexpression in iPSC-derived TS-like cells

    PMID:27965054

    Open questions at the time
    • Molecular machinery of nuclear import not defined
    • Direct TE target genes not ChIP-mapped
  13. 2015 High

    Positioned ARID3A as the effector node of the Lin28b/let-7 axis in B-1 lymphopoiesis, sufficient to impose fetal B-1 fate on adult progenitors and dependent on BCR signaling.

    Evidence Retroviral gain-of-function, let-7 modulation, shRNA knockdown, transplantation, BCR blockade

    PMID:25753579

    Open questions at the time
    • Direct B-1 fate target genes not mapped
    • Mechanistic link to BCR signaling unresolved
  14. 2016 Medium

    Defined an IFNα-producing ARID3A+ effector B cell subset, showing ARID3A is required for TLR9-driven IFNα production with paracrine activation of plasmacytoid dendritic cells.

    Evidence Flow sorting, CpG stimulation, IFNα detection, co-culture with pDCs

    PMID:27522115

    Open questions at the time
    • Direct ARID3A targets in IFNα program not identified
    • Relevance to autoimmunity correlative
  15. 2019 High

    Revealed an epigenetic-erasing role: ARID3A binds conserved regeneration enhancers at lhx1 and reduces H3K9me3 as part of demethylase complexes to drive cell-cycle progression and tubule regeneration.

    Evidence Enhancer screen, ChIP for Arid3a and H3K9me3, conditional photo-morpholino knockdown in Xenopus

    PMID:30616715

    Open questions at the time
    • Identity of the demethylase enzyme not defined here
    • Recruitment mechanism to RSREs unknown
  16. 2012 Medium

    Defined miRNA control of ARID3A in B-cell progenitors, with miR-125b directly repressing it to block differentiation and confer p53-independent survival.

    Evidence miRNA reporter validation, knockdown/overexpression, apoptosis assays, patient correlation

    PMID:22469780

    Open questions at the time
    • Anti-apoptotic effector downstream of ARID3A loss unidentified
    • Mechanism independent of p53/BAK1 unclear
  17. 2012 Medium

    Implicated ARID3A in viral chromatin architecture, showing it binds the EBV C promoter and forms a complex with E2F1, Oct-2, and EBNA1 mediating long-distance promoter-enhancer contacts during latency.

    Evidence DNA-affinity MS, Co-IP, proximity ligation assay, ChIP

    PMID:22302879

    Open questions at the time
    • Functional consequence for EBV gene expression not quantified here
    • Direct vs bridged interactions not separated
  18. 2020 Medium

    Showed extensive functional redundancy and cross-regulation with paralog ARID3B, with both inducing stem/cancer gene programs and each other's expression in ovarian cancer.

    Evidence Retroviral gain-of-function and RNA-seq with gene set enrichment

    PMID:32061921

    Open questions at the time
    • Direct vs indirect target distinction not made
    • Mechanism of mutual induction unknown
  19. 2021 Medium

    Linked ARID3A to oncogenic proliferation by showing it transcriptionally activates AURKA to drive colorectal cancer cell migration and invasion.

    Evidence Gain/loss-of-function, proliferation/migration/invasion assays, AURKA-dependent rescue

    PMID:33165575

    Open questions at the time
    • Direct binding at AURKA promoter not demonstrated
    • Single-lab
  20. 2022 High

    Integrated ARID3A into megakaryocytic differentiation and leukemia, showing it cooperates with GATA1 and forms a SMAD2/3 complex mediating TGF-β apoptosis, with miR-125b repression synergizing with Gata1s to drive AMKL.

    Evidence Forward/reverse genetics, SMAD2/3 Co-IP, miR-125b validation, xenograft rescue, differentiation assays

    PMID:34570885

    Open questions at the time
    • Direct ARID3A-GATA1 contact not shown
    • SMAD2/3 complex genomic targets not mapped
  21. 2022 High

    Defined an ARID3A-CEP131-KDM3A epigenetic cascade in which ARID3A activates the demethylase KDM3A to erase H3K9me2 at ES-signature loci, promoting stemness and metastasis in liver cancer.

    Evidence Co-IP, CUT&Tag, RNA-seq, ChIP at KDM3A promoter, in vitro/in vivo functional assays

    PMID:36008383

    Open questions at the time
    • Role of CEP131 in chromatin recruitment unclear
    • Direct ARID3A binding at ES loci vs KDM3A-mediated indirect effect not fully separated
  22. 2022 Medium

    Defined a porcine-ortholog regulatory axis in which NF-κB controls ARID3A nuclear import to repress the let-7 cluster, modulating viral replication.

    Evidence EMSA, ChIP, NF-κB inhibition, nuclear import analysis in alveolar macrophages

    PMID:36215225

    Open questions at the time
    • Mechanism by which NF-κB controls import undefined
    • Conservation in human cells not tested
  23. 2023 High

    Showed ARID3A directly represses Mertk in macrophages, with myeloid-specific loss enhancing efferocytosis and protecting against cholestatic liver injury.

    Evidence ChIP-seq, luciferase reporter, myeloid KO across three disease models, efferocytosis assay, pharmacological Mertk inhibition

    PMID:37659731

    Open questions at the time
    • Co-repressor partners at Mertk promoter not identified
    • Upstream control of ARID3A in macrophages unclear
  24. 2024 High

    Established ARID3A as a ferroptosis suppressor, showing it occupies and represses the PTEN promoter, and its loss triggers PTEN-driven GPX4 depletion, lipid peroxidation, and ferroptosis in pancreatic cancer.

    Evidence CUT&Tag, RNA-seq, knockdown, in vitro/in vivo tumor assays, ferroptosis markers

    PMID:38781729

    Open questions at the time
    • PTEN-to-GPX4 mechanistic link not fully resolved
    • Direct vs indirect repression details limited

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ARID3A's intrinsic DNA-binding specificity is reprogrammed to act as activator vs repressor in different cell types, and what governs its regulated nuclear translocation, remain unresolved.
  • No unified model of activator/repressor switching
  • Nuclear import machinery and signal-dependent regulation undefined
  • Composition of repressive vs activating ARID3A complexes incompletely mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5 GO:0098772 molecular function regulator activity 2
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-4839726 Chromatin organization 3
Partners
ARID3BBTKCEP131GATA1GTF2IID1SMAD2SMAD3
Complex memberships
ARID3A–CEP131 complexARID3A–SMAD2/3 complexBright–Btk–TFII-I IgH complex

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 Bright/ARID3A binds DNA through its ARID (A/T-rich interaction domain) and increases immunoglobulin heavy chain transcription 3-7 fold in antigen-activated B cells; Bruton's tyrosine kinase (Btk) is required for Bright binding activity, and Bright associates with nuclear matrix proteins sp100 and LYSp100B, suggesting roles in chromatin configuration and nuclear sublocalization. DNA binding assays, transcriptional reporter assays, protein-protein interaction studies Immunologic research Medium 11594453
2006 TFII-I directly interacts with Bright/ARID3A through amino acids in Bright's protein interaction domain; specific tyrosine residues of TFII-I (phosphorylated by Btk) are essential for Bright-induced immunoglobulin heavy chain reporter gene activity, establishing a three-component Bright–Btk–TFII-I complex at the immunoglobulin locus. Co-immunoprecipitation, reporter gene assay, dominant-negative TFII-I inhibition in B-cell lines, in vitro binding with deletion/point mutants Molecular and cellular biology High 16738337
2007 Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain (IgH) Eμ enhancer: Bright blocks nucleosome-mediated repression on chromatin-reconstituted templates, requires MAR (matrix attachment region) flanking sequences for maximal derepression, and increases DNase hypersensitivity of Eμ when added to B cell nuclear extracts. In vitro transcription on chromatin-reconstituted templates, DNase I hypersensitivity assay, competition with high-affinity P2 binding sites Molecular cancer High 17386101
2003 E2FBP1/DRIL1 (human ARID3A ortholog) is transcriptionally regulated by p53 via a p53-binding site in its second intron; its expression is induced by DNA damage (UV, doxorubicin) in a p53-dependent manner, and ectopic expression induces G1 growth arrest in p53-expressing cells but not p53-null cells. Luciferase reporter assay with p53-binding site, western blot after DNA damage, growth arrest assay in U2OS vs Saos-2 cells Molecular cancer research Medium 12692263
2008 ARID3A/Dril1 physically interacts with Id1 (co-localization in vitro and in vivo); Id1 inhibits DNA binding by Dril1; Dril1 enhances activation of TGF-β1 target genes in fibroblasts, while Id1 suppresses the same targets, providing a mechanism whereby Id1 suppresses fibrosis through inhibition of Dril1's profibrotic transcriptional activity. Protein interaction screening (yeast two-hybrid), co-localization by imaging, DNA-binding competition assay, TGF-β1 target gene expression analysis in Id1-knockout fibroblasts The American journal of pathology Medium 18583319
2010 Loss of Bright/ARID3A function in mouse models and human cells promotes developmental plasticity: Bright-deficient cells express pluripotency-associated gene products, expand indefinitely, and spontaneously differentiate into multiple lineages; direct knockdown of human Bright yields colonies capable of multi-lineage marker expression. Two mouse KO/inhibitor models, colony formation assay, lineage marker expression, siRNA knockdown of human ARID3A Stem cells Medium 20680960
2011 ARID3A/DRIL1 cooperates with p53 to transcriptionally activate p21WAF1: ARID3A binds its cognate sites in the p21WAF1 promoter in vivo (ChIP) and in vitro, co-expression with p53 synergistically activates the p21WAF1 promoter, mutation of ARID3A binding sites reduces promoter activity, and ARID3A knockdown suppresses p21WAF1 induction (but not NOXA or PUMA) after DNA damage. ARID3A overexpression/knockdown reciprocally modulates p53 protein stability. ChIP, EMSA, luciferase reporter with mutant binding sites, siRNA knockdown, western blot Biochemical and biophysical research communications High 22172947
2011 Brightlike/ARID3C physically associates with Bright/ARID3A in solution and at common DNA binding sites in vitro; it co-activates Bright-dependent IgH transcription without significant transactivation capacity of its own; the unsumoylated form shows maximal co-activation; Brightlike undergoes nuclear-cytoplasmic shuttling and localizes in lipid rafts after BCR stimulation. Co-immunoprecipitation, in vitro DNA binding assay, IgH reporter gene assay, sumoylation analysis, subcellular fractionation/localization Molecular immunology Medium 21955986
2012 miR-125b directly targets and represses Bright/ARID3A in B-cell progenitors; repression of ARID3A blocks B-cell differentiation, confers survival advantage under IL-3 starvation, and promotes anti-apoptotic effects via caspase blockade independent of p53 and BAK1. miRNA target validation (luciferase reporter), loss-of-function with ARID3A knockdown/overexpression, apoptosis assays, patient sample expression correlation Leukemia Medium 22469780
2012 ARID3A/Bright binds to the EBV C promoter (Cp) region and interacts with E2F1 and Oct-2; all three factors associate with EBNA1 in EBV-positive cell nuclei (co-IP and proximity ligation assay); ARID3A interaction was detected at Cp but not at the FR region of oriP, participating in long-distance promoter-enhancer interactions during EBV latency. DNA-affinity purification with mass spectrometry, co-immunoprecipitation, proximity ligation assay, ChIP The Journal of general virology Medium 22302879
2014 Bright/ARID3A acts as a barrier to somatic cell reprogramming by directly binding to promoter/enhancer regions of Oct4, Sox2, and Nanog and contributing to their repression in both MEFs and ESCs; Bright-deficient MEFs bypass senescence and spontaneously form pluripotent clones capable of teratoma formation and chimerism. ChIP at Oct4/Sox2/Nanog promoters, MEF reprogramming assay, teratoma/chimera formation, knockout MEF analysis Stem cell reports High 24511468
2014 Arid3a drives trophectoderm (TE) lineage commitment: nuclear entry of Arid3a activates TE-specific genes while directly repressing pluripotency genes via differential epigenetic regulation (acetylation/deacetylation at target loci); Arid3a null mice show severe placental defects causing early embryonic death; Arid3a acts upstream of and independently of Cdx2. ChIP for epigenetic marks, loss-of-function (Arid3a−/− mice), gain-of-function in ES cells, trophoblast stem cell assays Genes & development High 25319825
2015 Arid3a is a key target of let-7 microRNA downstream of Lin28b in fetal B-1 lymphopoiesis: modulation of let-7 in fetal pro-B cells alters B-1 development; ectopic Arid3a expression is sufficient to induce B-1 development in adult pro-B cells, and Arid3a knockdown blocks B-1 development in fetal pro-B cells; intact BCR signaling is required for Lin28b/Arid3a-induced B1a generation. Retroviral transduction, let-7 modulation, shRNA knockdown of Arid3a, transplantation into immunodeficient recipients, BCR signaling blockade The Journal of experimental medicine High 25753579
2016 ARID3A is required for mammalian placentation: it localizes to trophoblast giant cells and other trophoblast-derived subtypes; BMP4-mediated TS-like cell induction triggers cytoplasmic-to-nuclear translocation of ARID3A; ARID3A overexpression in BMP4-induced TS-like cells up-regulates TE markers and down-regulates pluripotency markers; null placentas show aberrant subtype-specific marker expression and altered cytokine/chemokine profiles. Immunohistochemistry/immunofluorescence for localization, conventional KO mouse model, ARID3A overexpression in human iPSC-derived TS-like cells, marker expression analysis Developmental biology Medium 27965054
2016 ARID3a+ human B lymphocytes constitute a novel effector B cell type that produces interferon alpha (IFNα); ARID3a expression is required for IFNα expression in B cells stimulated with TLR9 agonist CpG; IFNα secreted from ARID3a+ B cells stimulates increased IFNα production in plasmacytoid dendritic cells. Flow cytometry sorting of ARID3a+ B cells, CpG stimulation, ELISA/intracellular staining for IFNα, co-culture with pDCs Journal of autoimmunity Medium 27522115
2005 Dril1/ARID3A is necessary for TGF-β (activin/Smad2 and BMP/Smad1) signaling in Xenopus embryos: morpholino knockdown of dril1 inhibits gastrulation, blocks induction of mesodermal and endodermal markers by activin/Smad2, and prevents ventral mesoderm induction by Smad1, while FGF-mediated mesoderm induction is unaffected, demonstrating pathway specificity; phenotype is rescued by dril1 mRNA co-injection. Morpholino knockdown, mRNA rescue, engrailed-repressor fusion (dominant negative), animal cap assay, marker gene expression (RT-PCR) Developmental biology High 15680369
2019 Arid3a binds to regeneration signal-response enhancers (RSREs) at the lhx1 locus (conserved from fish to human) and reduces H3K9me3 levels at these elements as a component of H3K9me3 demethylase complexes; Arid3a promotes cell cycle progression and nephric tubule outgrowth during regeneration; conditional knockdown of arid3a by photo-morpholino inhibits nephric tubule regeneration in Xenopus. Enhancer screen, ChIP for H3K9me3 and Arid3a binding, photo-morpholino conditional knockdown, cell cycle analysis eLife High 30616715
2019 miR-574-5p directly targets ARID3A mRNA in human cardiac fibroblasts (HCFs); decreased ARID3A levels promote fibroblast-to-myofibroblast differentiation in TGF-β-stimulated HCFs, as evidenced by altered fibrosis gene expression, proliferation, migration, and invasion assays. miRNA target validation (luciferase reporter), siRNA/mimic transfection, fibrosis marker expression, proliferation/migration/invasion assays Biochemical and biophysical research communications Medium 31672272
2021 ARID3A promotes colorectal cancer cell proliferation, migration, and invasion by transcriptionally activating Aurora kinase A (AURKA); ARID3A overexpression enhances, while knockdown suppresses, these malignant phenotypes in a manner dependent on AURKA. ARID3A overexpression/knockdown, cell proliferation/migration/invasion assays, AURKA expression analysis, rescue experiments Carcinogenesis Medium 33165575
2022 ARID3A promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF-β-induced apoptosis and cell cycle arrest in a complex with SMAD2/3; posttranscriptional repression of ARID3A by miR-125b (encoded on chromosome 21) synergizes with Gata1s mutation to block megakaryocytic/erythroid differentiation and drive acute megakaryoblastic leukemia (AMKL); restoring ARID3A expression relieves differentiation block in AMKL patient-derived xenografts. Forward and reverse genetics, miR-125b target validation, SMAD2/3 co-immunoprecipitation, xenograft rescue experiments, flow cytometric differentiation assays Blood High 34570885
2022 ARID3A interacts with CEP131 and co-occupies the KDM3A promoter to transcriptionally activate KDM3A in liver cancer cells; KDM3A then demethylates H3K9me2 at downstream embryonic stem (ES) signature gene loci, upregulating their expression and promoting stemness and metastasis. Co-immunoprecipitation (ARID3A-CEP131), CUT&Tag chromatin profiling, RNA-seq, ChIP at KDM3A promoter, functional assays (viability, metastasis in vitro/in vivo) Cell death & disease High 36008383
2023 Arid3a negatively regulates Mertk transcription by directly binding to the Mertk promoter in macrophages; Arid3a-deficient macrophages show upregulated Mertk and enhanced efferocytosis of apoptotic cholangiocytes; myeloid-specific Arid3a knockout alleviates cholestatic liver injury in three murine models; in vitro Mertk inhibition reverses the protective phenotype of Arid3a deficiency. ChIP-seq for Arid3a at Mertk promoter, luciferase reporter assay, myeloid-specific KO mice, three cholestatic murine models, efferocytosis assay, pharmacological Mertk inhibition in vitro and in vivo Journal of hepatology High 37659731
2024 ARID3A transcriptionally represses PTEN in pancreatic cancer cells (CUT&Tag profiling shows ARID3A occupancy at PTEN promoter); decreased ARID3A relieves this repression, leading to PTEN upregulation, GPX4 depletion, increased lipid peroxidation, and ferroptosis activation, which suppresses tumor progression and gemcitabine resistance. CUT&Tag profiling, RNA-seq, ARID3A knockdown, in vitro and in vivo tumor assays, ferroptosis markers (lipid peroxidation, GPX4 levels) Redox biology High 38781729
1998 The human DRIL1 gene (ARID3A) encodes an ARID family DNA-binding protein; its exon-intron structure was determined and it was physically mapped within 80 kb of marker D19S886 on chromosome 19p13.3. cDNA cloning, genomic mapping, Southern blot, physical linkage analysis Genomics Medium 9722953
2020 ARID3A and its paralog ARID3B regulate nearly identical sets of genes in ovarian cancer cells (< 5% uniquely regulated), inducing stem cell and cancer-associated genes (Twist, MYCN, MMP2, GLI2, WNT5B); ARID3A and ARID3B also induce each other's expression, demonstrating cooperativity. Retroviral transduction of ARID3A-GFP and ARID3B-RFP, RNA-sequencing, gene set enrichment Gene Medium 32061921
2022 ARID3A (porcine ortholog) binds to the promoter region of the pri-let-7a/let-7f/let-7d gene cluster and inhibits let-7 family expression in porcine alveolar macrophages; the NF-κB signaling pathway inhibits let-7 expression by affecting the nuclear import of ARID3A; this regulatory axis modulates PRRSV-2 replication. EMSA, ChIP, NF-κB pathway inhibition, nuclear import analysis PLoS pathogens Medium 36215225

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 ROS in cancer therapy: the bright side of the moon. Experimental & molecular medicine 1515 32060354
2013 A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nature methods 1026 23524392
2016 mScarlet: a bright monomeric red fluorescent protein for cellular imaging. Nature methods 871 27869816
2016 The bright side of dark matter: lncRNAs in cancer. The Journal of clinical investigation 348 27479746
2014 RNA mango aptamer-fluorophore: a bright, high-affinity complex for RNA labeling and tracking. ACS chemical biology 347 25101481
2019 Bright and photostable chemigenetic indicators for extended in vivo voltage imaging. Science (New York, N.Y.) 344 31371562
2020 CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Molecular therapy : the journal of the American Society of Gene Therapy 292 32979309
2019 Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs. Nature biotechnology 277 31548726
2020 Extracellular vesicles: A bright star of nanomedicine. Biomaterials 275 33189359
2016 Bright monomeric near-infrared fluorescent proteins as tags and biosensors for multiscale imaging. Nature communications 235 27539380
1999 Reporter gene technology: the future looks bright. Biochemical pharmacology 223 10449183
2022 A highly photostable and bright green fluorescent protein. Nature biotechnology 219 35468954
2010 Oncogene-induced senescence: the bright and dark side of the response. Current opinion in cell biology 181 20807678
2020 Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals. Nature methods 145 32661427
2019 NanoBRET: The Bright Future of Proximity-Based Assays. Frontiers in bioengineering and biotechnology 133 30972335
2020 mGreenLantern: a bright monomeric fluorescent protein with rapid expression and cell filling properties for neuronal imaging. Proceedings of the National Academy of Sciences of the United States of America 128 33208539
2005 Anthocyans from fruits and vegetables--does bright colour signal cancer chemopreventive activity? European journal of cancer (Oxford, England : 1990) 124 16084717
2021 The bright side of fibroblasts: molecular signature and regenerative cues in major organs. NPJ Regenerative medicine 122 34376677
2018 Imaging organoids: a bright future ahead. Nature methods 112 29298292
2014 Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma. Pigment cell & melanoma research 110 24814217
1994 TOTO and YOYO: new very bright fluorochromes for DNA content analyses by flow cytometry. Cytometry 109 7513274
2015 Lin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a. The Journal of experimental medicine 107 25753579
2016 PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation. International journal of molecular sciences 93 27589732
2014 18F-Labeled Peptides: The Future Is Bright. Molecules (Basel, Switzerland) 91 25493636
2014 TIGAR, TIGAR, burning bright. Cancer & metabolism 90 24383451
2012 The bright and the dark sides of activin in wound healing and cancer. Journal of cell science 90 22991378
2017 A Bright Future for Serial Femtosecond Crystallography with XFELs. Trends in biochemical sciences 86 28733116
2007 Quantum dots and peptides: a bright future together. Biopolymers 80 17167795
2018 MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair. International journal of molecular sciences 76 30205559
2017 Cancer secretome and inflammation: The bright and the dark sides of NF-κB. Seminars in cell & developmental biology 75 28779979
2018 A bright future: optogenetics to dissect the spatiotemporal control of cell behavior. Current opinion in chemical biology 73 30529586
2024 Bright and stable monomeric green fluorescent protein derived from StayGold. Nature methods 67 38409224
2022 Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma. Environmental toxicology 66 35179300
2001 Green fluorescent protein--a bright idea for the study of bacterial protein localization. FEMS microbiology letters 60 11682170
2020 The bright and the dark sides of L-carnitine supplementation: a systematic review. Journal of the International Society of Sports Nutrition 58 32958033
2021 Bright and stable luminescent probes for target engagement profiling in live cells. Nature chemical biology 52 34675420
2006 Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I. Molecular and cellular biology 52 16738337
2012 B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. Leukemia 50 22469780
2015 Dark dyes-bright complexes: fluorogenic protein labeling. Current opinion in chemical biology 47 26056741
2022 CAR T-cell therapies in China: rapid evolution and a bright future. The Lancet. Haematology 46 36455608
2010 Loss of Bright/ARID3a function promotes developmental plasticity. Stem cells (Dayton, Ohio) 46 20680960
2022 CD39 - A bright target for cancer immunotherapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 45 35550530
2014 Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog. Stem cell reports 43 24511468
2014 Arid3a is essential to execution of the first cell fate decision via direct embryonic and extraembryonic transcriptional regulation. Genes & development 43 25319825
2023 Bright-Field and Edge-Enhanced Imaging Using an Electrically Tunable Dual-Mode Metalens. ACS nano 42 37490514
2017 Bright Polymer Dots Tracking Stem Cell Engraftment and Migration to Injured Mouse Liver. Theranostics 42 28638470
2023 Avidity-based bright and photostable light-up aptamers for single-molecule mRNA imaging. Nature chemical biology 41 36658339
2020 A Bright and Colorful Future for G-Protein Coupled Receptor Sensors. Frontiers in cellular neuroscience 41 32265667
2023 Protein dynamics: The future is bright and complicated! Structural dynamics (Melville, N.Y.) 40 36865927
2007 Creatine and creatine kinase in health and disease--a bright future ahead? Sub-cellular biochemistry 40 18652084
2024 Imaging the dynamics of messenger RNA with a bright and stable green fluorescent RNA. Nature chemical biology 38 38783134
2018 Sulfonylurea and neuroprotection: The bright side of the moon. Journal of advanced pharmaceutical technology & research 38 30637228
2023 Bright future or blind alley? CAR-T cell therapy for solid tumors. Frontiers in immunology 37 36761757
2004 CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clinical and experimental immunology 36 15270860
2021 ARID3A promotes the development of colorectal cancer by upregulating AURKA. Carcinogenesis 35 33165575
2020 Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery? Acta pharmaceutica Sinica. B 35 33777673
2010 A new bright green-emitting fluorescent protein--engineered monomeric and dimeric forms. The FEBS journal 35 20345907
2007 Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Molecular cancer 35 17386101
2023 A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis. Journal of hepatology 34 37659731
2019 Bright sub-20-nm cathodoluminescent nanoprobes for electron microscopy. Nature nanotechnology 34 30833691
2022 The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. Blood 32 34570885
2024 Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clinical and experimental medicine 30 39325256
2022 miRNA let-7 family regulated by NEAT1 and ARID3A/NF-κB inhibits PRRSV-2 replication in vitro and in vivo. PLoS pathogens 30 36215225
2016 ARID3A is required for mammalian placenta development. Developmental biology 30 27965054
2024 The role of CD56bright NK cells in neurodegenerative disorders. Journal of neuroinflammation 29 38350967
2010 The bright and the dark sides of DNA repair in stem cells. Journal of biomedicine & biotechnology 29 20396397
2014 The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis. Frontiers in immunology 28 24678314
2013 Bright ion channels and lipid bilayers. Accounts of chemical research 28 23597020
2003 E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. Molecular cancer research : MCR 28 12692263
2024 ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Redox biology 27 38781729
2020 ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells. Gene 27 32061921
2016 Human effector B lymphocytes express ARID3a and secrete interferon alpha. Journal of autoimmunity 26 27522115
2019 Arid3a regulates nephric tubule regeneration via evolutionarily conserved regeneration signal-response enhancers. eLife 25 30616715
2018 Building on Success: A Bright Future for Peptide Therapeutics. Protein and peptide letters 25 30430932
2021 Amplified Fluorescence in Situ Hybridization by Small and Bright Dye-Loaded Polymeric Nanoparticles. ACS nano 24 34928570
2019 Haem Biology in Metazoan Parasites - 'The Bright Side of Haem'. Trends in parasitology 24 30686614
2019 Vaccine vectors: the bright side of cytomegalovirus. Medical microbiology and immunology 24 30900089
2018 ARID3a gene profiles are strongly associated with human interferon alpha production. Journal of autoimmunity 24 30297159
1998 The human dead ringer/bright homolog, DRIL1: cDNA cloning, gene structure, and mapping to D19S886, a marker on 19p13.3 that is strictly linked to the Peutz-Jeghers syndrome. Genomics 24 9722953
2020 Getting DNA and RNA out of the dark with 2CNqA: a bright adenine analogue and interbase FRET donor. Nucleic acids research 23 32558908
2011 Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. Molecular immunology 23 21955986
2008 Cross talk between Id1 and its interactive protein Dril1 mediate fibroblast responses to transforming growth factor-beta in pulmonary fibrosis. The American journal of pathology 23 18583319
2024 The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management. Cancers 22 39061221
2021 Extracting quantitative biological information from bright-field cell images using deep learning. Biophysics reviews 22 38505631
2019 Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation. Frontiers in immunology 22 30930899
2015 The Transcription Factor ARID3a Is Important for In Vitro Differentiation of Human Hematopoietic Progenitors. Journal of immunology (Baltimore, Md. : 1950) 22 26685208
2022 Hepatic ARID3A facilitates liver cancer malignancy by cooperating with CEP131 to regulate an embryonic stem cell-like gene signature. Cell death & disease 21 36008383
2019 The Bright and Dark Side of DNA Methylation: A Matter of Balance. Cells 20 31614870
2019 MiR-574-5p promotes the differentiation of human cardiac fibroblasts via regulating ARID3A. Biochemical and biophysical research communications 20 31672272
2017 Flow cytometry in Spermatology: A bright future ahead. Reproduction in domestic animals = Zuchthygiene 20 28815751
2012 E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein-Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions. The Journal of general virology 20 22302879
2023 Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star? International journal of molecular sciences 19 36674884
2011 Cooperation between ARID3A and p53 in the transcriptional activation of p21WAF1 in response to DNA damage. Biochemical and biophysical research communications 19 22172947
2019 Bright G-Quadruplex Nanostructures Functionalized with Porphyrin Lanterns. Journal of the American Chemical Society 18 31322869
2022 Engineering Bright and Mechanosensitive Alkaline-Earth Rare-Earth Upconverting Nanoparticles. The journal of physical chemistry letters 17 35133831
2005 The ARID domain protein dril1 is necessary for TGF(beta) signaling in Xenopus embryos. Developmental biology 17 15680369
2024 2X-Rhodamine: A Bright and Fluorogenic Scaffold for Developing Near-Infrared Chemigenetic Indicators. Journal of the American Chemical Society 16 38605649
2023 Diversified Mammalian Visuasl Adaptations to Bright- or Dim-Light Environments. Molecular biology and evolution 16 36929909
2021 Novel Strategy in Breast Cancer Therapy: Revealing The Bright Side of Ginsenosides. Current molecular pharmacology 16 33494691
2001 The transcription factor, Bright, and immunoglobulin heavy chain expression. Immunologic research 15 11594453

Missed literature

Know a paper Affinage missed for ARID3A? Flag it for the maintainers and the community.

No submissions yet.